UCB S.A.
UCB
Rang in aandelen
#527
UCB S.A., a biopharmaceutical enterprise founded in 1925 and headquartered in... UCB S.A., a biopharmaceutical enterprise founded in 1925 and headquartered in Brussels, Belgium, focuses on developing innovative solutions for individuals living with neurological and immunological diseases. Its diverse commercialized portfolio includes Cimzia, targeting inflammatory TNF-mediated conditions such as Crohn's disease, various forms of spondyloarthritis, rheumatoid arthritis, and psoriasis. For epilepsy management, UCB offers Vimpat, Keppra, and Briviact, along with Nayzilam, an intranasal rescue treatment for seizure clusters. Neupro is available for Parkinson's disease and restless legs syndrome, while Zyrtec and Xyzal address allergy symptoms. Other key products include Evenity for osteoporosis in postmenopausal women, and BIMZELX, which treats psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa. The company also provides dapirolizumab pegol for systemic lupus erythematosus. UCB's robust development pipeline features candidates like rozanolixizumab, aimed at myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan for myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam for prolonged seizures; Bepranemab for Alzheimer's disease; and UCB0599 for Parkinson's disease. Beyond its proprietary drug development, UCB also conducts contract manufacturing. The company engages in significant collaborations with entities such as Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. UCB's global footprint extends across numerous countries, including the United States, Japan, China, Belgium, and a broad presence throughout Europe, encompassing Germany, Spain, France, Italy, the United Kingdom, and Ireland.
Aandeelprijs
$242.09
Laatst gesynchroniseerd: 2026-10-16
Marktkapitalisatie
$46.16B
Verandering (1 dag)
-0.92%
Verandering (1 jaar)
-16.48%
Land
BE
Handel UCB S.A. (UCB)
Categorie
Healthcare
Operationele marge voor UCB S.A. (UCB)
Operationele marge op October 2026 TTM: 31.23%
Volgens de meest recente financiële rapporten en aandelenkoers van UCB S.A. is de huidige operationele marge (TTM) 31.23%. Eind 2023 had het bedrijf een operationele marge van 11.50%.
Geschiedenis van de operationele marge van UCB S.A. van 2002 tot 2026
Operationele marge aan het einde van elk jaar
| Jaar | Operationele Marge | Wijzigen |
|---|---|---|
| 2026 (TTM) | 31.23% | 45.12% |
| 2024 | 21.52% | 87.13% |
| 2023 | 11.50% | 58.62% |
| 2022 | 7.25% | -63.48% |
| 2021 | 19.85% | 8.65% |
| 2020 | 18.27% | -17.18% |
| 2019 | 22.06% | -8.12% |
| 2018 | 24.01% | -0.08% |
| 2017 | 24.03% | 25.22% |
| 2016 | 19.19% | 28.88% |
| 2015 | 14.89% | 31.07% |
| 2014 | 11.36% | 16.27% |
| 2013 | 9.77% | -13.08% |
| 2012 | 11.24% | 6.04% |
| 2011 | 10.60% | 67.19% |
| 2010 | 6.34% | -76.40% |
| 2009 | 26.86% | 755.41% |
| 2008 | 3.14% | -66.91% |
| 2007 | 9.49% | -58.06% |
| 2006 | 22.63% | 45.53% |
| 2005 | 15.55% | 13.50% |
| 2004 | 13.70% | -6.29% |
| 2003 | 14.62% | 64.09% |
| 2002 | 8.91% | 0.00% |
Operationele marge van vergelijkbare bedrijven of concurrenten
| Bedrijf | Operationele Marge | Verschil in operationele marge | Land |
|---|---|---|---|
| 38.59% | -98.76% |
US
|
|
| -149.01% | -104.77% |
US
|
|
| 25.57% | -99.18% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -99.08% |
NL
|
Wat is de Operationele marge van een bedrijf?
De Operationele marge is een belangrijke indicator om de winstgevendheid van een bedrijf te beoordelen. Hogere operationele marges zijn over het algemeen beter omdat ze aangeven dat een bedrijf zijn producten of diensten veel duurder kan verkopen dan de productiekosten. De Operationele marge wordt berekend door de winst van een bedrijf te delen door de omzet.